TITLE

Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons

AUTHOR(S)
Pattacini, Laura; Murnane, Pamela M.; Baeten, Jared M.; Fluharty, Tayler R.; Thomas, Katherine K.; Bukusi, Elizabeth; Katabira, Elly; Mugo, Nelly; Donnell, Deborah; Lingappa, Jairam R.; Celum, Connie; Marzinke, Mark; McElrath, M. Juliana; Lund, Jennifer M.
PUB. DATE
June 2015
SOURCE
Journal of Infectious Diseases;6/15/2015, Vol. 211 Issue 12, p1943
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Antiretroviral preexposure prophylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency virus (HIV) prevention strategy for populations at high risk of HIV acquisition. Although the primary mode of action for the protective effect of PrEP is probably direct antiviral activity, nonhuman primate studies suggest that PrEP may also allow for development of HIV-specific immune responses, hypothesized to result from aborted HIV infections providing a source of immunologic priming. We sought to evaluate whether PrEP affects the development of HIV-specific immune response in humans. Methods and Results. Within a PrEP clinical trial among high-risk heterosexual African men and women, we detected HIV-specific CD4+ and CD8+ peripheral blood T-cell responses in 10%-20% of 247 subjects evaluated. The response rate and magnitude of T-cell responses did not vary significantly between those assigned PrEP versus placebo, and no significant difference between those assigned PrEP and placebo was observed in measures of innate immune function. Conclusions. We found no evidence to support the hypothesis that PrEP alters either the frequency or magnitude of HIV-specific immune responses in HIV-1-exposed seronegative individuals. These results suggest that PrEP is unlikely to serve as an immunologic prime to aid protection by a putative HIV vaccine
ACCESSION #
103100197

 

Related Articles

  • Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects. Dieye, Tandakha N.; NDiaye, Birahim P.; Dieng, Alle B.; Fall, Marema; Britain, Nathaniel; Vermaak, Samantha; Camara, Makhtar; Diop-Ndiaye, Halimatou; Ngom-Gueye, Ndeye Fatou; Diaw, Papa A.; Toure-Kane, Coumba; Sow, Papa S.; Mboup, Souleymane; McShane, Helen // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Tuberculosis (TB) is a global public health problem exacerbated by the HIV epidemic. Here we evaluate a candidate TB vaccine, MVA85A, in a Phase I study in HIV-infected adults in Senegal. 24 patients were enrolled: Group 1∶12, antiretroviral therapy (ART) naïve, adults, with CD4 counts...

  • Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. Wagh, Kshitij; Bhattacharya, Tanmoy; Williamson, Carolyn; Robles, Alex; Bayne, Madeleine; Garrity, Jetta; Rist, Michael; Rademeyer, Cecilia; Yoon, Hyejin; Lapedes, Alan; Gao, Hongmei; Greene, Kelli; Louder, Mark K.; Kong, Rui; Karim, Salim Abdool; Burton, Dennis R.; Barouch, Dan H.; Nussenzweig, Michel C.; Mascola, John R.; Morris, Lynn // PLoS Pathogens;3/30/2016, Vol. 12 Issue 3, p1 

    The identification of a new generation of potent broadly neutralizing HIV-1 antibodies (bnAbs) has generated substantial interest in their potential use for the prevention and/or treatment of HIV-1 infection. While combinations of bnAbs targeting distinct epitopes on the viral envelope (Env)...

  • Pre-Exposure Prophylaxis for HIV. Maynard, Tony // HIV Australia;Jul-Sep2005, Vol. 5 Issue 1, p23 

    Provides information on pre-exposure prophylaxis (PREP) for HIV which involves HIV negative people using antiretrovirals prior to engaging in activities that may lead to HIV transmission such as unprotected sex. Information on clinical trials to prove that using PREP could prevent infection;...

  • Combination of IMODâ„¢ and Arbidol to increase their immunomodulatory effects as a novel medicine to prevent and cure influenza and some other infectious diseases. Arastoo, Mahmoud; Khorram Khorshid, Hamid Reza; Radmanesh, Ramin; Gharibdoust, Farhad // Journal of Medical Hypotheses & Ideas;Jul2014, Vol. 8 Issue 2, p53 

    Highlights: [•] A better choice to prevent and cure viral infectious diseases will be established. [•] Individual treatment effects of IMOD and Arbidol will be increased. [•] Infectious diseases such as influenza and hepatitis B/C can be targeted. [•] Antioxidant...

  • T Cell Chemo-Vaccination Effects after Repeated Mucosal SHIV Exposures and Oral Pre-Exposure Prophylaxis. Kersh, Ellen N.; Adams, Debra R.; Youngpairoj, Ae S.; Wei Luo; Qi Zheng; Mian-er Cong; Wutyi Aung; Mitchell, James; Otten, Ron; Hendry, R. Michael; Heneine, Walid; McNicholl, Janet; Garcia-Lerma, J. Gerardo // PLoS ONE;2011, Vol. 6 Issue 4, p1 

    Pre-exposure prophylaxis (PrEP) with anti-viral drugs is currently in clinical trials for the prevention of HIV infection. Induction of adaptive immune responses to virus exposures during anti-viral drug administration, i.e., a ''chemovaccination'' effect, could contribute to PrEP efficacy. To...

  • Relationship between HIV/Highly Active Antiretroviral Therapy (HAART)—Associated Lipodystrophy Syndrome and Stavudine-Triphosphate Intracellular Levels in Patients with Stavudine-Based Antiretroviral Regimens. Domingo, Pere; Cabeza, Maria Carmen; Pruvost, Alain; Salazar, Juliana; del Mar Gutierrez, Maria; Mateo, Maria Gracia; Domingo, Joan C.; Fernandez, Irene; Villarroya, Francesc; Muñoz, Jessica; Vidal, Francesc; Baiget, Montserrat // Clinical Infectious Diseases;4/1/2010, Vol. 50 Issue 7, p1033 

    Background. The link between human immunodeficiency virus/highly active antiretroviral therapy (HAART)- associated lipodystrophy syndrome (HALS) and the use of thymidine analogues has been well established. However, to our knowledge, no relationship has been proven between intracellular levels...

  • Recurrent hypersensitivity to Combivir. Winston, Alan; McLean, Ken // International Journal of STD & AIDS;Mar2002, Vol. 13 Issue 3, p213 

    The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly used in combination antiretroviral therapy and are associated with hypersensitivity reactions on induction therapy. We report a case of recurrent hypersensitivity associated with Combivir, when there was a delay in...

  • Experimental approaches to the study of HIV-1 latency. Han, Yefei; Wind-Rotolo, Megan; Yang, Hung-Chih; Siliciano, Janet D.; Siliciano, Robert F. // Nature Reviews Microbiology;Feb2007, Vol. 5 Issue 2, p95 

    Viral latency is a reversibly non-productive state of infection that allows some viruses to evade host immune responses. As a consequence of its tropism for activated CD4+ T cells, HIV-1 can establish latent infection in resting memory CD4+ T cells, which are generated when activated CD4+ T...

  • HIV Controllers: A Homogeneous Group of HIV-1-Infected Patients with Spontaneous Control of Viral Replication. Lambotte, Olivier; Boufassa, Faroudy; Madec, Yoann; Nguyen, Ahn; Goujard, Cécile; Meyer, Laurence; Rouzioux, Christine; Venet, Alain; Delfraissy, Jean-François // Clinical Infectious Diseases;10/1/2005, Vol. 41 Issue 7, p1053 

    We identified a total 15 patients who have maintained undetectable plasma HIV RNA loads without antiretroviral treatment for >10 years from cohorts of 1300 and 1551 patients infected with human immunodeficiency virus (HIV). These 15 patients, whom we have referred to as "HIV controllers," are...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics